A peptide and an active metabolite of GLP-1 (7-36) amide
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

GLP-1 (28-36) amide (trifluoroacetate salt)

Item No. 41249

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-argininamide, trifluoroacetate salt
Synonyms
  • Glucagon-like Peptide 1 (28-36) amide
  • Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2
Molecular Formula
C54H85N15O9 • XCF3COOH
Formula Weight
1088.4
Purity
≥98%
Formulation (Request formulation change)
A solid
Peptide Sequence
FIAWLVKGR-NH2
Solubility(Learn about Variance in Solubility)
Acetonitrile: Slightly soluble: 0.1-1 mg/mlChloroform: Slightly soluble: 0.1-1 mg/mlMethanol: Slightly soluble: 0.1-1 mg/ml
SMILES
[H]N[C@H](C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCNC(N)=N)C(N)=O)=O)=O)=O)=O)=O)CC1=CNC2=C1C=CC=C2)=O)C)=O)=O)CC3=CC=CC=C3.FC(F)(F)C(O)=O
InChi Code
InChI=1S/C54H85N15O9.C2HF3O2/c1-8-32(6)45(69-48(73)37(56)26-34-17-10-9-11-18-34)53(78)63-33(7)47(72)66-42(27-35-28-61-38-20-13-12-19-36(35)38)50(75)67-41(25-30(2)3)51(76)68-44(31(4)5)52(77)65-40(21-14-15-23-55)49(74)62-29-43(70)64-39(46(57)71)22-16-24-60-54(58)59;3-2(4,5)1(6)7/h9-13,17-20,28,30-33,37,39-42,44-45,61H,8,14-16,21-27,29,55-56H2,1-7H3,(H2,57,71)(H,62,74)(H,63,78)(H,64,70)(H,65,77)(H,66,72)(H,67,75)(H,68,76)(H,69,73)(H4,58,59,60);(H,6,7)/t32-,33-,37-,39-,40-,41-,42-,44-,45-;/m0./s1
InChi Key
AJGPKINDFLQSCY-OPOSQYSSSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $31

    Add

    5 mg

    $131

    Add

    10 mg

    $216

    Add

    25 mg

    $501

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Glucagon-like peptide 1 (GLP-1) (28-36) amide is a peptide and an active metabolite of the endogenous GLP-1R agonist GLP-1 (7-36) amide (Item No. 15069).1,2 It is formed from GLP-1 (7-36) amide by neprilysin (NEP).2 GLP-1 (28-36) amide (100 nM) inhibits decreases in ATP levels induced by hydrogen peroxide and increases in reactive oxygen species (ROS) levels induced by tert-butyl hydroperoxide (t-BHP) in primary mouse hepatocytes and H-4-II-E hepatoma cells.1 It reduces body weight gain, the ratio of weight gain to food intake, and hepatic gluconeogenesis in a mouse model of obesity induced by a high-fat diet (HFD) when administered at a dose of 18.5 nmol/kg per day.3 GLP-1 (28-36) amide decreases plasma levels of glucose and insulin and hepatic triglyceride levels in a mouse model of obesity induced by a very high-fat diet (VHFD) when infused at a rate of 18.5 nmol/kg per day.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Tomas, E., Stanojevic, V., and Habener, J.F. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul. Pept. 167(2-3), 177-184 (2011).

    2. Hupe-Sodmann, K., McGregor, G.P., Bridenbaugh, R., et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. 58(3), 149-156 (1995).

    3. Ip, W., Shao, W., Chiang, Y.-t.A., et al. GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice. Am. J. Physiol. Endocrinol. Metab. 305(11), E1348-E1358 (2013).

    4. Tomas, E., Wood, J.A., Stanojevic, V., et al. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice. Regul. Pept. 169(1-3), 43-48 (2011).